Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

All news Pharmasist News & insight

GLP-1 drugs for eating disorders: Nov. 17 review finds mixed evidence and flags risks

Some small studies suggest a benefit for binge-eating symptoms, but a pilot trial found no clear advantage over placebo. The review also raises concerns about restrictive eating.

2 min read3 sources
Share LinkedIn X Facebook Email
Illustrative photo accompanying this news article
An Ozempic pen, shown as an example of a GLP-1 medicine. Photo: Dennis Sylvester Hurd / Wikimedia Commons, CC0. Image source
In this article & details

Article details

Published
Nov 17, 2026
Reading time
2 min read
Categories
Clinical Research, Medication Safety
Jurisdiction
National
Sources cited
3
All news

A review published Nov. 17 in Current Psychiatry Reports found mixed evidence on whether GLP-1 receptor agonists improve binge-eating symptoms and warned that the same effects on appetite could make restrictive eating harder to detect. The authors reviewed existing studies; they did not report results from a new clinical trial.

Observational findings and a small trial point in different directions

The authors found that some studies reported larger reductions in binge-eating symptoms with GLP-1 drugs than with comparison medicines. One was a retrospective study of semaglutide, meaning the researchers looked at treatment that had already taken place rather than assigning participants to groups. A small randomized pilot study of liraglutide did not find a statistically significant advantage over placebo for the binge-eating outcome. The review pointed to the need for stronger evidence before drawing conclusions about benefit.

That distinction matters because a change in appetite or body weight is not the same as sustained improvement in an eating disorder. The review discusses possible effects on food reward and compulsive eating, but says the evidence base remains sparse.

Appetite suppression may obscure restrictive symptoms

The authors raised a different concern for people vulnerable to anorexia nervosa or atypical anorexia nervosa: a medicine that suppresses appetite could facilitate or conceal restrictive eating. They noted that people with eating disorders were excluded from clinical development trials, leaving limited evidence about how often these harms occur. The review describes a possible risk, not a measured rate of new or recurrent eating disorders.

The review does not change Canadian product indications

Health Canada identifies GLP-1 medicines as prescription drugs with authorized uses that include type 2 diabetes or obesity, depending on the product. The Canadian Wegovy product record and monograph do not list treatment of an eating disorder as an indication. The review calls for better studies of how these drugs affect different eating disorders, including the safety and durability of any benefit.

References

  1. Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders — Current Psychiatry Reports, Open-access review, Nov. 17, 2026
  2. Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? — Health Canada, Canadian prescription and authorization context
  3. Wegovy: Canadian product information and monograph — Health Canada Drug Product Database, Product indications

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.